SCHEMBL9945708

SCHEMBL9945708

CCCCN(C)CCCC(C)C

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GGPS1 O95749 3/20 0.38
S1PR2 O95136 1/20 0.36
S1PR1 P21453 1/20 0.36
S1PR3 Q99500 1/20 0.36
S1PR5 Q9H228 1/20 0.36
KDM4C Q9H3R0 5/20 0.36
KDM5A P29375 4/20 0.36
LMNA P02545 1/20 0.36
DNM1 Q05193 2/20 0.35
PLA2G1B P04054 1/20 0.34
PLA2G2A P14555 1/20 0.34
PHF8 Q9UPP1 1/20 0.34
KDM4A O75164 1/20 0.34
OPRM1 P35372 1/20 0.33
CHRM2 P08172 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23948096 0.93 GGPS1 (0.41) GGPS1S1PR2S1PR1S1PR3S1PR5
SCHEMBL17831487 0.93 GGPS1 (0.46) GGPS1S1PR2S1PR1S1PR3S1PR5
SCHEMBL25761406 0.91 GGPS1 (0.44) GGPS1S1PR2S1PR1S1PR3S1PR5
SCHEMBL28092012 0.91 GGPS1 (0.44) GGPS1S1PR2S1PR1S1PR3S1PR5
SCHEMBL23879755 0.91 GGPS1 (0.48) GGPS1S1PR2S1PR1S1PR3S1PR5
SCHEMBL25562392 0.91 GGPS1 (0.44) GGPS1S1PR2S1PR1S1PR3S1PR5
SCHEMBL172303 0.90 SIGMAR1 (0.38) GGPS1S1PR2S1PR1S1PR3S1PR5
SCHEMBL18251199 0.90 GGPS1 (0.38) GGPS1S1PR2S1PR1S1PR3S1PR5
SCHEMBL4122365 0.89 LMNA (0.43) GGPS1KDM4CLMNAPHF8KDM4A
SCHEMBL22957162 0.88 GGPS1 (0.46) GGPS1S1PR2S1PR1S1PR3S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293706-A1 Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery MEDICI THERAPEUTICS, INC. 2023-09-21 US disclosed
WO-2023141279-A2 TERPENE-CONTAINING LIPIDOIDS FOR GENE DELIVERY UNIVERSITY OF SAN DIEGO (US) 2023-07-27 WO disclosed
US-11701434-B2 Tertiary amino lipidated cationic peptides for nucleic acid delivery NUTCRACKER THERAPEUTICS, INC. (US) 2023-07-18 US disclosed
US-20230183253-A1 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY RHODE ISLAND HOSPITAL 2023-06-15 US disclosed
US-20190209702-A1 STEROIDS AND ANTIBODY-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. 2019-07-11 US disclosed
US-20170362238-A1 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY RHODE ISLAND HOSPITAL 2017-12-21 US disclosed
US-20170320977-A1 OLEFIN POLYMERIZATION CATALYST SYSTEM COMPRISING MESOPOROUS ORGANOSILICA SUPPORT EXXONMOBIL RESEARCH AND ENGINEERING COMPANY 2017-11-09 US disclosed
US-8562966-B2 End-modified poly(beta-amino esters) and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2013-10-22 US disclosed
US-20120149630-A1 END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190209702-A1 STEROIDS AND ANTIBODY-CONJUGATES THEREOF SERPINA6, NR3C1, NR3C2 GGPS1 1197/4885S1PR2 1883/4885S1PR1 1511/4885
US-20120149630-A1 END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF PARN, PARG, POLL GGPS1 3114/4885S1PR2 3036/4885S1PR1 2500/4885
US-20230293706-A1 Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery MTREX, EXOSC5, KPNA6 GGPS1 2371/4885S1PR2 1937/4885S1PR1 2204/4885
US-11701434-B2 Tertiary amino lipidated cationic peptides for nucleic acid delivery LNPEP, SLC7A1, APLNR GGPS1 3962/4885S1PR2 1738/4885S1PR1 1810/4885
US-20170362238-A1 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY POLRMT, NT5C3B, CHMP4B GGPS1 2341/4885S1PR2 4106/4885S1PR1 3995/4885
US-20230183253-A1 NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY POLRMT, NT5C3B, CHMP4B GGPS1 2341/4885S1PR2 4106/4885S1PR1 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.